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Biglycan and decorin are small dermatan sulfate-con-
taining proteoglycans in the extracellular matrix of the
artery wall. The dermatan sulfate chains are known to
stimulate thrombin inhibition by heparin cofactor II
(HCII), a plasma proteinase inhibitor that has been de-
tected within the artery wall. The purpose of this study
was to analyze the HCII-stimulatory activity of biglycan
and decorin isolated from normal human aorta and ath-
erosclerotic lesions type II through VI and to correlate
activity with dermatan sulfate chain composition and
structure. Biglycan and decorin from plaque exhibited a
24–75% and 38–79% loss of activity, respectively, in
thrombin-HCII inhibition assays relative to proteogly-
can from normal aorta. A significant negative linear
relationship was observed between lesion severity and
HCII stimulatory activity (r 5 0.79, biglycan; r 5 0.63,
decorin; p < 0.05). Biglycan, but not decorin, from ath-
erosclerotic plaque contained significantly reduced
amounts of iduronic acid and disulfated disaccharides
DDi-2,4S and DDi-4,6S relative to proteoglycan from nor-
mal artery. Affinity coelectrophoresis analysis of a sub-
set of samples demonstrated that increased interaction
of proteoglycan with HCII in agarose gels paralleled
increased activity in thrombin-HCII inhibition assays.
In conclusion, both biglycan and decorin from athero-
sclerotic plaque possessed reduced activity with HCII,
but only biglycan demonstrated a correlation between
activity and specific glycosaminoglycan structural fea-
tures. Loss of the ability of biglycan and decorin in ath-
erosclerotic lesions to regulate thrombin activity
through HCII may be critical in the progression of the
disease.
Biglycan and decorin are small leucine-rich dermatan sulfate
(DS)1-containing proteoglycans (PGs) found in the extracellu-
lar matrix of connective tissues such as skin, bone, and carti-
lage. Biglycan and decorin have also been detected in the artery
wall (1). They are composed of distinct core proteins linked to
one (decorin) or two (biglycan) DS chains (2) that consist of
alternating hexuronic acid and N-acetylgalactosamine resi-
dues. The DS chains are heterogeneous in the extent of post-
translational modifications such as the conversion of glucu-
ronic acid to its epimer iduronic acid and sulfation at the C-4
and C-6 positions of N-acetylgalactosamine and the C-2 posi-
tion of iduronic acid (3). The predominant disaccharide in
mammalian DS is hexuronic acid-N-acetylgalactosamine-4-sul-
fate, but small amounts of “oversulfated” disaccharides con-
taining two or three sulfates are also usually detectable. Nu-
merous structural studies have been carried out on DS from
mucosa, skin, and cartilage. The chain composition appears to
be distinct for specific tissues and species (2, 4). However,
relatively little is known about the structure of human arterial
DSPG in health or disease. DS content is elevated in athero-
sclerotic plaque compared with normal aorta (5), and DSPGs
produced by cultured aortic smooth muscle cells exhibit altered
sulfation patterns after treatment with platelet-derived growth
factor and transforming growth factor-b (6), two cytokines im-
plicated in atherosclerosis. Thus, changes in arterial DSPG
may occur in the human atherosclerotic plaque but have not
been reported.
DS chains (7, 8) and DSPG (9, 10) greatly increase the rate of
thrombin inhibition by heparin cofactor II (HCII). Thrombin is
an enzyme with procoagulant (11), chemoattractant (12, 13),
and mitogenic activities (14, 15) that is generated at sites of
vascular injury. Thrombin is thought to contribute to athero-
genesis (16–18). HCII, a glycosaminoglycan (GAG)-binding
plasma proteinase inhibitor and member of the serpin super-
family of proteins (19), inhibits thrombin by forming an inac-
tive bimolecular complex with the enzyme. The inhibition re-
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action is accelerated by DS or DSPG (through the DS moiety) in
a dose-dependent manner, up to several thousand-fold at opti-
mal concentrations (7, 8). A specific DS hexasaccharide se-
quence composed of repeats of iduronic acid 2-sulfate 3 N-
acetylgalactosamine 4-sulfate has been shown to bind to HCII
(20). Given the selectivity with which DS activates HCII among
all of the GAG-binding serpins and the presence of DSPG in the
extracellular matrix of a wide variety of tissues, HCII has been
proposed to be an inhibitor of “extravascular” thrombin activity
(i.e. released or generated outside the circulation due to vascu-
lar damage) and to be activated physiologically by DSPG (7–
10). Isolated biglycan and decorin from skin and cartilage have
been shown to accelerate thrombin-HCII inhibition reactions
(10). In addition, DSPGs synthesized by cultured fibroblasts (9)
and arterial smooth muscle cells (21) accelerate the rate of
thrombin inhibition by HCII. Recently, an immunohistochem-
ical study indicated that HCII is distributed throughout the
intima beneath the endothelium of normal human arteries
(22). The presence of both DSPG and HCII within the arterial
wall is consistent with a role for DSPG-stimulated HCII inhi-
bition of intramural thrombin activity. If changes in arterial
DSPG structure occur during the progression of atherosclero-
sis, the thrombin-inhibitory activity of HCII may be altered,
thus affecting the proatherogenic activity of thrombin.
The purpose of the present study was to investigate the
structure and HCII-stimulatory activity of human aortic bigly-
can and decorin and to determine possible changes that occur
in atherosclerosis. Biglycan and decorin were isolated from
normal aorta and atherosclerotic lesions of varying severity.
The DSPGs were compared for activity in thrombin-HCII as-
says and for GAG composition. The results indicate that bigly-
can and decorin from atherosclerotic lesions exhibit both al-
tered structure and reduced activity compared with DSPG from
normal aorta.
EXPERIMENTAL PROCEDURES
Materials—Human arterial biglycan and decorin were isolated as
described below. Porcine skin DS was obtained from Calbiochem and
nitrous acid-treated as described previously (23) to remove contaminat-
ing heparin. HCII (24) and thrombin (25) were purified as described.
The thrombin chromogenic substrate, tosyl-Gly-Pro-Arg-p-nitroanilide
(Chromozym-TH), was purchased from Roche Molecular Biochemicals,
and Polybrene was from Sigma. Chondroitinase ABC (EC 4.2.2.4) and
chondroitinase ACII (EC 4.2.2.5) were obtained from Seikagaku Amer-
ica, Inc. Low melting point agarose (SeaPlaque) and GelBond were from
FMC Bioproducts. For affinity coelectrophoresis (ACE) experiments,
heparin from porcine intestinal mucosa (Sigma) was substituted with
tyramine at the reducing end, radiolabeled with 125I to a specific activ-
ity of ;30,000 cpm/ng using the IODO-GEN method (Pierce), and
size-fractionated by Sephadex G-100 chromatography as described (26).
Porcine skin DS was radioiodinated using the IODO-GEN method
without prior substitution with tyramine, and the HCII-binding frac-
tion was recovered by adsorption to HCII-Sepharose in 50 mM Tris-HCl
(pH 7.4), 50 mM NaCl (20).
Isolation of Human Arterial Biglycan and Decorin—Human aortas
from four individuals were obtained at autopsy less than 8 h postmor-
tem through the autopsy service of Wake Forest University Medical
Center (Winston-Salem, NC). The four autopsy cases were as follows:
A421, a 31-year-old female with nephritis determined as the cause of
death; A127, a 59-year-old male with heart failure; A243, a 27-year-old
female with sepsis; and A507, a 52-year-old female with emphysema.
Intima preparations were made by stripping vessels under 3 10 mag-
nification. Atherosclerotic lesions, identified grossly according to the
American Heart Association classification scheme (27), and adjacent
normal aorta were excised, minced, and then extracted with buffer (15
ml/g of wet tissue) containing 4 M GdnHCl in 0.05 M sodium acetate (pH
4.5) with 100 mM 6-aminohexanoic acid, 5 mM benzamidine, 3 mM
o-phenanthroline, and 5 mM tryptamine HCl. Extracts were filtered on
Whatman no. 1 paper, concentrated in an Amicon stirred-cell concen-
trator with YM30 membrane, and dialyzed into buffer containing 7 M
urea, 0.05 M sodium acetate (pH 7.2), 0.15 M NaCl. Dialyzed samples
were applied to DEAE Sephacel columns (15–25-ml bed volume) equil-
ibrated and washed with 7 M urea in 0.05 M Tris-HCl (pH 7.2), 0.15 M
NaCl. The column was eluted stepwise with equilibrating buffer con-
taining 0.35 M NaCl to elute heparan sulfate PG and then with 1 M NaCl
to elute the DSPG and chondroitin sulfate-containing PG pool. The 1 M
NaCl fraction was concentrated; dialyzed against 4 M GdnHCl, 0.05 M
sodium acetate (pH 5.8); and chromatographed on a Sepharose CL-4B
column (1.5 3 78 cm). Collected fractions were analyzed for PG with the
dimethylmethylene blue dye-binding assay (28). The CL-4B peak elut-
ing at a Kav of ;0.6 contained the biglycan and decorin, which were
subsequently separated by octyl-Sepharose chromatography as de-
scribed previously (2). First an aliquot of DSPG was radiolabeled with
14C and mixed with unlabeled DSPG to monitor the separation of
biglycan and decorin. 14C labeling of PG was done by reductive alkyla-
tion with 14C-labeled formaldehyde by the procedure of Jentoft and
Dearborn (29) as adopted by Parthasarathy and Tanzer (30). For each
sample, DSPG plus 106 dpm of 14C-labeled PG was loaded onto a 1-ml
octyl-Sepharose column equilibrated with 4 M GdnHCl, 0.15 M sodium
acetate (pH 6.3). Decorin was obtained in the column flow-through
(unbound fraction), and biglycan was eluted with 1% CHAPS in
GdnHCl/acetate buffer. Fig. 1 illustrates the effective separation of
labeled decorin and biglycan in normal aorta and type IV lesion from
autopsy case A421. For all samples used in this study, the octyl-Sepha-
rose elution profiles were similar to Fig. 1. Purity of decorin and bigly-
can was evaluated based on the absence of extraneous protein on
Coomassie Blue-stained 4–12% SDS-polyacrylamide gels. The identity
of decorin and biglycan was assessed by SDS-polyacrylamide gel elec-
trophoresis of intact PG and core proteins prepared with chondroitinase
ABC treatment and by recognition by core-specific antibodies on West-
ern blots. For normal and atherosclerotic lesions, molecular weights
were similar to reported values for intact decorin and biglycan and
enzyme-generated core proteins (2). In addition, in view of the limited
information available on aortic biglycan, one 20-mg sample representing
5 mg of protein pooled from each of the four biglycan samples from
normal aorta was examined by N-terminal sequence analysis. This
sample was digested with chondroitinase ABC, subjected to SDS-poly-
acrylamide gel electrophoresis, and transferred onto polyvinylidene
difluoride membrane. One band of 47 kDa was generated following
FIG. 1. Elution profile of decorin and biglycan from octyl-
Sepharose. DSPG isolated from A421 normal aorta (A) and A421 type
IV lesion (B) that eluted from Sepharose CL-4B were chromatographed
on octyl-Sepharose. Decorin (peak 1) was eluted with 4.0 M GdnHCl,
0.15 M sodium acetate (pH 6.3). Biglycan (peak 2) was eluted with the
same buffer containing 1% CHAPS.
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digestion. The band was divided into top, middle, and bottom. Each part
was excised from the polyvinylidene difluoride membrane and se-
quenced. The amino acid sequence obtained for all three samples (11,
16, and 16 residues, respectively) was identical to the reported sequence
of human bone biglycan (31).
For structural analysis of the GAG chains, biglycan and decorin core
proteins were removed by digestion with papain as described previously
(32). For ACE experiments, biglycan and decorin core proteins were
labeled with 125I by the chloramine T method (33).
Thrombin Inhibition Assays—Inhibition assays were performed as
described previously (21) at ambient temperature. Reaction mixtures
contained 50 nM HCII, 5 nM thrombin, 2 mg/ml bovine serum albumin,
and PG or GAG at the indicated concentration of hexuronic acid in
buffer containing 20 mM HEPES, pH 7.4, 150 mM NaCl, 1 mg/ml
polyethylene glycol, and 0.02% NaN3. Fifty-ml inhibition reactions were
begun with the addition of thrombin. After the appropriate incubation
period, the reaction was quenched, and residual thrombin activity was
measured by the addition of 135 ml of 0.2 mM Chromozym TH contain-
ing 2 mg/ml Polybrene. Color development was quenched with the
addition of 50 ml of 8.7 M glacial acetic acid, and the absorbance was
read at 405 nm. Second order inhibition rate constants were calculated
as k2 5 2ln(a)/t[I] where a is the fractional thrombin activity remaining
relative to a thrombin control containing the same components minus
HCII, t is incubation time, and I is the initial inhibitor concentration.
Each assay consisted of triplicate determinations, and except where
indicated, the mean 6 S.E. of three assays is reported.
Determination of GAG Molecular Weight—DS apparent molecular
weights were determined by Sepharose 6B chromatography essentially
as described (34). DS isolated by papain digestion was pooled using
equivalent amounts of hexuronic acid from either normal artery sam-
ples or type V lesion samples. They were subject to b-elimination
followed by reduction with [3H]NaBH4 (35) and chromatographed on a
1.5 3 90-cm column of Sepharose 6B (Amersham Pharmacia Biotech)
that was eluted with 0.2 M NaCl at a flow rate of 11.5 ml/h. Apparent
molecular weights were determined by comparison of elution position
with published calibration curves (34) that were confirmed with three
[3H]GAG standards of known molecular weight obtained from the Na-
tional Institutes of Health.
Determination of Iduronic Acid Content—Iduronic acid content was
determined by measuring the amount of unsaturated disaccharides
produced from 10 mg of hexuronic acid of DS chains by digestion with
either chondroitinase ABC (for total hexuronic acid-containing disac-
charides, denoted UA below; DUA represents 4-deoxy-a-L threo-hex-4-
enopyranosyluronic acid) or chondroitinase ACII (for glucuronic acid-
containing disaccharides, denoted GluA) (36). Iduronic acid content was
calculated as follows.
% IdoA 5 @~total DUA 2 GluA)/total DUA] 3 100% (Eq. 1)
Disaccharide Analysis—DS (2 mg of hexuronic acid) was digested
with chondroitinase ABC to produce unsaturated disaccharides. One-
tenth of the sample (;200 ng) was chromatographed in buffer contain-
ing 70% acetonitrile/methanol (3:1, v/v) and 30% 0.5 M ammonium
acetate, pH 5.3, on a 250 3 4.6-mm Partisil-10 PAC column (Whatman).
Peaks detected at 232 nm were identified by comparison with retention
times for unsulfated, monosulfated, and disulfated disaccharide stand-
ards obtained from Seikagaku America, Inc. Percentage composition
was calculated from the sum of peak areas. The mean value of three or
more runs is reported.
ACE—GAG- and PG-protein interactions were analyzed by ACE as
described (26, 37). ACE gels were made of 1% SeaKem low melting point
agarose in 50 mM MOPSO (pH 7.0), 125 mM sodium acetate, 0.5%
CHAPS buffer. They contained nine parallel rectangular wells (4 3 15
mm) filled with nine different concentrations of HCII embedded in
agarose and a single slot (65 3 1 mm) positioned 3 mm above the top of
and perpendicular to the wells. The gels were submerged in MOPSO/
sodium acetate buffer in a submarine electrophoresis chamber, and
;10,000 cpm (,1 ng) of radiolabeled PG or GAG in electrophoresis
buffer containing 5% sucrose and tracking dyes was loaded into the slot
above the well. The PG or GAG was electrophoresed through the HCII-
containing wells at 20 °C for 1 h at 76 V. The gels were dried, and PG
or GAG mobility was measured with a PhosphorImager (Molecular
Dynamics). Each protein lane was scanned from top to bottom to meas-
ure relative radioactivity content per 88-mm pixel, and a distribution
curve for each lane was determined. PG or GAG mobility in each lane
was defined as the pixel position that divided the distribution curve into
halves. The PG or GAG retardation coefficient (R) was calculated for
each lane as the mobility shift in the protein-containing lane divided by
the mobility in a protein-free zone (r 5 (M0 2 M)/M0, where M0 is the
mobility of free PG or GAG and M is the mobility through protein).
Curve fitting of binding isotherms and calculation of apparent Kd were
performed as described (26).
ACE analysis of biglycan and decorin required the following modifi-
cations. The radiolabeled DSPG samples were found to contain a co-
purifying minor contaminant that may have potentially interfered with
analysis of PG migration on ACE gels. The contaminant migrated as a
discrete slow-moving front on ACE gels, was resistant to chondroitinase
ABC digestion and noninteractive with 5 mM HCII or 2 mM collagen type
I in ACE gels, and was thus determined not to be a DSPG. To remove
the contaminant, radiolabeled decorin and biglycan were subjected to
preparative ACE in block gels containing 1 mM collagen type I, as
described (26). The DSPGs were retained at the top of the gels through
binding to collagen and were thus resolved from the faster migrating
unbound contaminant. After electrophoresis, the portion of the ACE gel
containing the contaminant was cut away and discarded, and the
DSPG-containing gel segments were then melted, pooled, and made 6 M
urea for loading into analytical ACE gels (urea prevents the molten
agarose from gelling, does not migrate in an electrophoretic field, and
prevents renaturation of the collagen). Analytical gels were poured that
each contained only three agarose lanes, one with 5 mM HCII and two
lacking protein. Following electrophoresis of biglycan and decorin
through these gels, DSPG retardation coefficients (R) at 5 mM HCII
were calculated as described above.
Statistical Analysis—Results of the experimental studies are re-
ported as mean 6 S.E. unless otherwise noted. Differences between
means were assessed either by Student’s t test or by one-way analysis
of variance followed by Tukey’s test for mean separation. Probability
values of ,0.05 were considered significant. No data were transformed
prior to analyses.
RESULTS
Properties of Proteoglycans in Human Aorta—Human arte-
rial biglycan and decorin were isolated from the aorta intima
tissue of four different individuals obtained at autopsy. Total
proteoglycan isolated by GdnHCl extraction was similar to our
previous reports (5, 38) and the reports of others (39) for human
aorta. For this study, mean hexuronic acid concentrations
ranged from 379 to 502 mg/g of wet tissue (Table I). Depending
upon lesion type, approximately 63–83% of the PG was ac-
counted for by a mixture of chondroitin sulfate PG (versican)
and DSPG (decorin and biglycan) eluting from DEAE-Sephacel
with 1.0 M NaCl (Table I). Heparan sulfate PG accounted for
approximately 12–22% of the total PG based on hexuronic acid
analysis of the 0.35 M NaCl eluate. DSPG were separated from
versican by chromatography on Sepharose CL-4B. Following
hexuronic acid analysis of the DSPG, normal aorta and lesion
types II, IV, and V, respectively, comprised 27 6 6, 37 6 3, 31 6
2, and 43 6 5% (mean 6 S.E.) total PG (Table I). Increased
amounts of biglycan were observed in type IV lesions, where
the biglycan/decorin ratio was significantly greater (p , 0.05)
compared with normal aorta.
Human Arterial Biglycan and Decorin from Normal Aorta
Accelerate Thrombin Inhibition by HCII—The DSPG samples
were analyzed for activity in inhibition assays to determine the
ability to accelerate the rate of thrombin inhibition by HCII. At
1 mg of hexuronic acid/ml, human DSPG from normal aorta
increased the rate of thrombin inhibition several hundred-fold
TABLE I
Proteoglycans prepared from human aortic tissue











mg/g % of total mg/g
Normal aorta 487 6 40 63 6 5 133 6 33 0.25 6 0.03
Lesion type II 502 6 124 75 6 6 187 6 64 0.35 6 0.02
Lesion type IV 421 6 80 72 6 6 131 6 30 0.60 6 0.12a
Lesion type V 379 6 66 83 6 5 163 6 28 0.44 6 0.17
a Lesion type IV . normal aorta, p , 0.05.
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over the inhibition rate in the absence of PG (k2 5 4.1 3 10
4
M21 min21) (Fig. 2A). Some variation between individuals was
observed, but normal arterial biglycan consistently exhibited
between 2- and 4-fold greater activity than decorin from the
same tissue source. Human arterial DSPG had less activity
than porcine skin DS (see legend to Fig. 2A). The effect of
biglycan and decorin concentration on thrombin inhibition
rates was determined for selected samples. Over the range of
concentrations tested, a dose-dependent effect was observed for
normal artery biglycan and decorin from autopsy A243 (Fig.
2B) and for porcine skin DS (data not shown). At each concen-
tration, the consistent decreasing order of activity was as fol-
lows: skin DS . arterial biglycan . arterial decorin (Fig. 2B).
Arterial Biglycan and Decorin from Atherosclerotic Lesions
Have Reduced Activity in Thrombin-HCII Inhibition Reac-
tions—The activity of biglycan and decorin isolated from ath-
erosclerotic lesion types II through VI was next compared with
normal artery DSPG. Lesion biglycan exhibited a 24–75% loss
of activity, and lesion decorin exhibited a 38–79% loss of activ-
ity in thrombin-HCII inhibition assays relative to normal ar-
tery DSPG from the same autopsy case (Fig. 3). In no case was
the activity of lesion decorin or biglycan equal to or greater
than the corresponding normal artery DSPG. For both biglycan
and decorin, a significant negative linear relationship of inhi-
bition rate and atherosclerosis progression was observed. The
correlation coefficient for biglycan was 0.79 (p , 0.001), and the
value for decorin was 0.63 (p , 0.05).
Biglycan and Decorin from Atherosclerotic Plaque Exhibit
Altered Structural Features—The structure of biglycan and
decorin GAG chains was analyzed in an attempt to explain the
functional differences observed. We first determined by using
gel filtration chromatography whether there were differences
in the GAG molecular size between normal artery versus
plaque DSPG. However, the lack of sufficient material for sev-
eral samples precluded molecular weight determinations for all
30 samples. Instead, DS chains were analyzed from normal
artery and type V atherosclerotic lesion. For this purpose,
equal amounts of DS chains were pooled from two autopsy
samples: A421 and A507 for normal artery biglycan and A421
and A127 for type V lesion biglycan, type V lesion decorin, and
normal artery decorin. The apparent molecular mass of the
pooled normal artery biglycan and type V lesion biglycan was
30,521 and 41,058 daltons, respectively. The molecular mass of
pooled normal artery decorin and type V lesion decorin was
28,566 and 33,797 daltons, respectively.
Iduronic acid-rich DS sequences have been associated with
the stimulation of HCII activity. Iduronic acid content was
measured by susceptibility to chondroitinase ABC and resist-
ance to chondroitinase ACII digestion. The mean iduronic acid
content for normal arterial biglycan and decorin comprised 67
and 22%, respectively, of total hexuronic acid and differed
significantly (p , 0.01) (Table II). In addition, biglycan from
atherosclerotic lesion consistently contained reduced (p ,
0.002) amounts of iduronic acid relative to normal artery (Table
II). The mean iduronic acid content for biglycan from all lesion
FIG. 2. Human arterial biglycan and decorin from normal
aorta accelerate thrombin-HCII inhibition reactions. A, the ac-
tivity of normal human artery biglycan DSPG (black bars) and decorin
DSPG (hatched bars) from four separate autopsies (denoted with the
letter A followed by a number) was analyzed in thrombin-HCII inhibi-
tion reactions. Reactions contained 50 nM HCII, 5 nM thrombin, and 1
mg of hexuronic acid/ml of DSPG. For comparison, the rate constant (k2)
obtained with 1 mg/ml porcine skin DS was 9.2 6 0.3 3 107 M21 min21,
and the k2 in the absence of added DSPG or DS was 4.1 6 0.4 3 10
4 M21
min21. The mean 6 S.E. of three independent assays is reported. B, the
effect of DSPG concentration on the thrombin-HCII inhibition rate was
determined using normal arterial biglycan (E) and decorin (f) from
autopsy A243. The mean of two independent assays is reported.
FIG. 3. Comparison of activity of human arterial DSPG from
normal aorta and atherosclerotic lesion. The activity of biglycan
(A) and decorin (B) isolated from normal aorta (NA) and atherosclerotic
lesion types II, IV, V, and VI of four autopsy cases (l, A421; M, A127;
Œ, A243; ƒ, A507) was analyzed in thrombin-HCII inhibition assays at
a fixed concentration of 1 mg hexuronic acid/ml. Inhibition rates
(mean 6 S.E., n 5 3) for plaque DSPG are reported relative to the
inhibition rate for normal artery DSPG from the corresponding autopsy
case (defined as 1.0).
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types was 32%. No significant reductions in iduronic acid con-
tent were observed for decorin from atherosclerotic plaques.
Disaccharide composition was determined by reverse phase
high performance liquid chromatography analysis on a Partisil
PAC 10 column after GAG digestion with chondroitinase ABC.
Monosulfated disaccharides constituted a major portion (78–
97%) of total disaccharides, with DDi-4S being the predominant
disaccharide for both biglycan and decorin (Table II). However,
the ratio of DDi-6S to DDi-4S for decorin was approximately
twice as high as that of biglycan. The disulfated disaccharides
DDi-2,4diS and DDi-4,6diS together constituted a small per-
centage of the total, ranging from 0 to 8%. The percentage of
disulfated disaccharides was reduced relative to normal artery
biglycan in 8 of 11 plaque biglycan samples for DDi-2,4diS and
in 9 of 11 samples for DDi-4,6diS (Table II). The mean DDi-
2,4diS content for normal artery biglycan was 2.7% of the total
disaccharides and decreased to 1.3, 0.7, 0.2, and 0% for lesion
type II, type IV, type V, and type VI biglycan, respectively. The
mean 6 S.E. for DDi-2,4diS content in biglycan for all lesion
types (0.78 6 0.25%) was significantly reduced (p , 0.05)
compared with normal aorta. Likewise, DDi-4,6diS content for
biglycan from all lesion types (0.63 6 0.32%, mean 6 S.E.) was
significantly lower compared with normal aorta (2.2 6 0.72%).
There was no significant change in disulfated disaccharide
content for plaque decorin.
Relationship between DSPG Activity and Composition—Nor-
mal artery biglycan and normal artery decorin demonstrated a
positive correlation between activity in thrombin-HCII inhibi-
tion assays (i.e. inhibition rates) and iduronic acid content
(Table III). Normal artery and plaque biglycan samples also
exhibited a significant positive correlation between iduronic
acid content and activity in thrombin-HCII assays (Table III).
For biglycan, there was a positive correlation between activity
in thrombin-HCII assays and DDi-2,4diS content or DDi-2,4diS
plus DDi-4,6diS content, but there was no significant correla-
tion for biglycan activity versus DDi-4,6diS content alone (Ta-
ble III). Decorin did not show a significant correlation between
activity and DDi-2,4diS content, DDi-4,6diS content, or DDi-
2,4diS plus DDi-4,6diS content.
Differences in DSPG Activity in Thrombin-HCII Assays Cor-
relate with Differences in Binding to DSPG—The accelerating
effect of DS and DSPG on thrombin inhibition by HCII is
thought to be due to binding of GAG to HCII. Because the
observed differences in DS chain composition did not appear to
account for all of the differences in DSPG activity, we next
determined if variation in DSPG activity reflects differences in
binding affinity for HCII. The technique of ACE was applied
because it detects even weak binding events characteristic of
protein interactions with PG or GAG. Binding is detected un-
der nondenaturing conditions and at physiological ionic
strength as the retardation of PG electrophoretic migration
through protein-containing lanes of a 1% agarose gel. The
reduction in PG mobility (i.e. retardation coefficient, R) is pro-
portional to fractional saturation of the PG or GAG by protein.
The equilibrium binding constant (Kd) can be determined from
the relationship between R and protein concentration, as re-
ported previously for the interaction of heparin with anti-
thrombin and selected matrix proteins (37). To first validate
the ACE method for the study of HCII-GAG interactions, the
binding of HCII to size-fractionated heparin was examined.
The Kd of 212 nM (Fig. 4) was measured for medium molecular
weight 125I-tyramine-heparin (excluding the ;12% of mole-
cules lowest in Mr as well as the ;12% highest in Mr and
chosen as representative of the “average” heparin molecule),
which compares favorably with a previously reported Kd of 230
nM for unfractionated heparin and HCII (8). Four aortic DSPG
samples with different HCII activities and porcine skin DS
were next analyzed by ACE. Saturating concentrations of HCII
could not be achieved due to weak binding (Kd . 5 mM) and
limited supply of protein, and therefore complete binding iso-
therms and Kd values were not obtained. Instead, retardation
coefficients were measured at a fixed concentration of 5 mM
HCII to determine differences between 125I-DSPG samples in
binding to HCII. Fig. 5 illustrates that while 5 mM HCII induces
less than 25% retardation in DSPG or DS migration, the rank-
ing of DSPG/DS samples by apparent binding to HCII (repre-
TABLE II
Disaccharide composition (percentage of total)
Iduronic acid content (IdoA, percentage of total hexuronic acid) and unsaturated disaccharide (DDi-) composition were determined as described
under “Experimental Procedures.” Significant differences for biglycan are as follows: IdoA, normal . all lesion types, p , 0.002; IdoA, normal .
lesion II, p , 0.003; IdoA, normal . lesion IV, p , 0.03; IdoA, normal . lesion V, p , 0.02; 2,4-diS, normal . all lesion types, p , 0.05; 4,6-diS,
normal . all lesion types, p , 0.04. ND, not determined.
Tissue source
Biglycan DSPG Decorin DSPG
IdoA DDi-0-S DDi-6-S DDi-4-S DDi-2,4-diS DDi-4,6-diS IdoA DDi-0-S DDi-6-S DDi-4-S DDi-2,4-diS DDi-4,6-diS
Human aorta
A421
Normal 60.0 14.0 18.2 59.9 6.1 1.8 21.1 7.4 38.4 52.2 1.2 0.8
Lesion II 31.8 15.7 25.5 58.8 0.0 0.0 12.0 7.9 43.5 48.7 0.0 0.0
Lesion IV 45.2 1.2 23.6 70.6 1.2 3.3 14.7 5.3 38.6 53.8 1.1 1.1
Lesion V 42.0 6.5 21.7 70.9 0.4 0.6 17.8 4.0 44.1 50.0 1.0 0.8
A127
Normal 73.6 7.4 16.9 74.0 0.5 1.3 26.4 5.0 34.3 59.0 0.9 0.7
Lesion II 47.3 2.8 19.0 75.9 1.4 0.8 32.7 6.5 29.8 62.0 0.9 0.8
Lesion IV 45.6 5.0 13.3 80.9 0.8 0.0 44.3 4.8 27.5 65.5 1.2 1.0
Lesion V 46.2 2.1 24.1 73.2 0.1 0.5 42.8 12.5 21.0 64.4 1.3 0.9
Lesion VI 44.1 7.8 15.4 76.8 0.0 0.0 47.2 4.1 24.3 69.5 0.9 1.2
A243
Normal 72.3 4.7 19.1 72.3 2.6 1.3 23.7 3.2 34.4 60.6 1.1 0.7
Lesion II 16.6 5.5 24.8 67.2 2.2 0.3 24.5 ND ND ND ND ND
A507
Normal 62.2 6.5 26.1 61.7 1.4 4.3 16.9 4.2 46.9 47.8 0.7 0.4
Lesion II 13.9 4.8 34.4 58.0 1.7 1.2 11.0 6.3 49.6 42.5 0.8 0.9
Lesion IV 7.7 3.7 25.6 70.7 0.0 0.0 19.3 7.1 43.2 48.1 1.1 0.5
Lesion V 7.2 5.4 37.2 57.3 0.0 0.0 19.1 14.5 38.2 45.4 1.2 0.7
DS chains
Porcine skin ND 3.3 4.8 82.4 4.9 4.6
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sented by R9) or by HCII cofactor activity (k2) is identical. A
second experiment showed the same pattern with the exception
of a single outlier. These results demonstrate that the in-
creased activity of artery-derived DSPG in thrombin-HCII in-
hibition assays is associated with increased apparent affinity
for HCII.
DISCUSSION
Arterial DSPG has been implicated as having various roles
in the artery wall, including the regulation of collagen fibrillo-
genesis (40), the binding of cytokines (40) and lipoproteins (41),
and the stimulation of HCII activity (9, 10). All of these activ-
ities have been attributed at least in part to the DS moiety,
although the fine structure of the DS may vary between differ-
ent cells or tissues. Despite these reports indicating structure-
function interrelationships of DS, no information is available
on human aortic DSPG structure. The goal of the present study
was to assess and compare the structure and HCII stimulatory
activity of biglycan and decorin from normal aorta and to
determine whether functional and structural alterations occur
in these PGs during atherosclerosis. The main results of the
study indicate that there is a loss in the ability of DS to inhibit
artery wall thrombin through the activity of HCII as athero-
sclerosis progresses.
Both biglycan and decorin from normal artery were found to
accelerate the rate of thrombin inhibition by HCII in a dose-
dependent manner, with biglycan stimulating a larger rate
increase than equal hexuronic acid amounts of decorin. Inter-
estingly, both biglycan and decorin isolated from atheroscle-
rotic plaque exhibited reduced activity in thrombin-HCII inhi-
bition assays compared with the normal artery-derived PG.
Compositional analysis indicated that iduronic acid content
was significantly greater in biglycan than decorin from normal
artery and that iduronic acid content was significantly reduced
in plaque biglycan versus normal artery biglycan. The predom-
inant disaccharide for both biglycan and decorin was DDi-4S,
but decorin contained on average a greater percentage of
DDi-6S than biglycan. The majority of biglycan samples from
atherosclerotic plaque contained reduced amounts of the disul-
fated disaccharides. On average, lesion types had significant
reductions in both DDi-2,4diS and DDi-4,6diS compared with
normal aorta. There was no such pattern of reduced iduronic
acid or disulfated disaccharide content for plaque decorin.
With one notable exception, previous studies of DS structure
(4, 42–45) used material isolated without knowing whether
they were derived from decorin or biglycan. These studies,
which were performed on total DS derived from a variety of
mostly nonhuman tissues such as skin, intestinal mucosa,
liver, spleen, and aorta, demonstrated that DS was a copolymer
containing both glucuronic acid- and iduronic acid-containing
disaccharides that are sulfated mainly on the C-4 position of
N-acetylgalactosamine. Differences in DS disaccharide compo-
sition have been observed between preparations from different
tissue sources or from the same tissue but different species (2,
4). Our data are consistent with the range of values previously
reported. An iduronic acid content of 60% in normal artery
biglycan approaches the ;80% iduronic acid found in bovine
skin DS (2) and porcine skin DS (42), while the iduronic acid
TABLE III
Relationship of DSPG activity and GAG composition
Linear regression analysis of thrombin-HCII inhibition rate (k2, measured at 1 mg of hexuronic acid/ml of DSPG) plotted versus percentage
composition of specified disaccharide components. n is the sample size, and r is the correlation coefficient.
DSPGa Component n r Significance
Biglycan and Decorin, NA only IdoA 8 0.82 p , 0.05
Biglycan, NA and PQ IdoA 15 0.75 p , 0.01
Biglycan, NA and PQ DDi-2,4diS 15 0.65 p , 0.01
Biglycan, NA and PQ DDi-4,6diS 15 0.41 NS
Biglycan, NA and PQ DDi-2,4diS 1 DDi-4,6diS 15 0.64 p , 0.01
Decorin, NA and PQ IdoA 15 0.38 NS
Decorin, NA and PQ DDi-2,4diS 14 0.29 NS
Decorin, NA and PQ DDi-4,6diS 14 0.19 NS
Decorin, NA and PQ DDi-2,4diS 1 DDi-4,6diS 14 0.27 NS
a NA, normal aorta; PQ, plaque; NS, not significant.
FIG. 4. ACE analysis of HCII-heparin interaction. Calculation of
apparent affinity of HCII for size-fractionated medium molecular
weight 125I-Tyr-heparin. The heparin retardation coefficient (R) for
each protein-containing lane was determined as described under “Ex-
perimental Procedures” and is plotted versus HCII concentration. The
smooth curve represents nonlinear least-squares fit to the equation, r 5
R`/(1 1 Kd/[protein]
2), where R` 5 R at saturating concentrations of
protein. R` 5 0.73 for HCII, due to high mobility of HCII toward the
cathode in the electrophoretic field. A representative experiment is
shown.
FIG. 5. Relationship between DSPG activity and interaction
with HCII in ACE gels. Porcine skin DS (l), human normal aorta
biglycan (f) and normal aorta decorin (Œ), and type II lesion biglycan
() and type II lesion decorin (l) from autopsy A421 were subjected to
ACE analysis. The thrombin-HCII inhibition rate (k2) measured with 1
mg of hexuronic acid/ml of DSPG is plotted versus the normalized
retardation coefficient (R9) of 125I-DSPG or DS in ACE gel lanes con-
taining a 5 mM HCII. R9 5 R/R`, where R` is as defined in the legend to
Fig. 3. Results shown are from a single experiment.
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content of ;30% in normal artery decorin is closer to the
reported levels for human skin DS (43), equine aorta DS (45),
and bovine cartilage DS (2). Human arterial biglycan and
decorin have a DDi-4S content comparable with horse aorta DS
(;67%) (45) but appreciably less than the DDi-4S of ;85%
reported for porcine skin DS and bovine mucosa DS (44).
In only one other study have DS chains from biglycan and
decorin been examined separately. Choi and Rosenberg (2)
isolated intact biglycan and decorin from bovine cartilage and
skin and found striking tissue specificity of iduronic acid con-
tent. Biglycan and decorin from bovine skin contained ;80%
iduronic acid, whereas both PG in cartilage contained only
;35% iduronic acid (2), demonstrating that DSPG containing
the same core protein can have very different DS chains. Our
findings suggest, however, that two different core proteins from
the same tissue can have distinct DS compositions. While both
biglycan and decorin are synthesized by smooth muscle cells in
the artery wall, their distribution between interstitial and peri-
cellular matrices differ (46). Apparently, the cellular GAG mod-
ification machinery is sensitive to a variety of regulatory influ-
ences. The changes observed in GAG composition of biglycan
from normal artery versus atherosclerotic plaque suggest that
the presence of disease can also modify smooth muscle cell
metabolism and result in altered structure of DS chains.
The identification of structural features required for the
stimulation of HCII by DS has been the subject of numerous
studies. Highly charged DS preparations enriched in iduronic
acid and the disulfated disaccharides have been shown to have
the greatest activity. A high affinity hexasaccharide composed
of the repeating disaccharide iduronic acid 2-sulfate 3 N-
acetylgalactosamine 4-sulfate has been identified in porcine DS
(20), and DDi-4,6diS has been found to contribute to the activity
expressed by DDi-2,4S-enriched sequences (44, 47). Iduronic
acid seems to be important in that it can be sulfated at the C-2
position, while its epimer glucuronic acid is rarely sulfated.
Because of the conformational flexibility of iduronic acid in the
polymer, the resulting oligosaccharide could provide highly
charged clusters of sulfate groups with high specificity for
HCII, as has been described for other GAG-protein interactions
(48). The positive correlation between the disulfated disaccha-
rides and iduronic acid content of human artery biglycan and
the activity in thrombin-HCII inhibition assays supports the
importance of a specific sulfation pattern for the interaction
with HCII. In contrast, human arterial decorin did not demon-
strate the same correlation. However, the organization of dis-
ulfated disaccharides within DS appears to be crucial, and the
current study does not attempt to determine the sequence of
the DS chains. Oligosaccharide blocks consisting of three or
more iduronic acid-containing disulfated disaccharides are re-
quired for binding to HCII (20). The reduced activity of plaque
decorin compared with normal artery decorin may result from
a lack of block structure due to random distribution of the
disulfated disaccharides.
DS accelerates the HCII-thrombin inhibition reaction in a
dose-dependent manner (7, 8). Therefore, a rigorous compari-
son of the activity of GAG or PG in thrombin-HCII inhibition
reactions requires that the assays be performed with equimolar
concentrations of DSPG/DS. In the present study, equal
amounts of hexuronic acid were used for activity comparisons
instead, since limited sample size prohibited molecular weight
measurements on all samples. Yet GAG molecular weight
measurements made on mixtures of two normal artery or
plaque biglycan and decorin samples suggest that DS chain
length may increase as atherosclerosis progresses. To the best
of our knowledge, there are no reports of the specific effect of
chain length on HCII activity beyond the minimum of 14–18
saccharide units (;4000 daltons) required for full activity (49,
50). Therefore, the reduced activity of plaque versus normal
artery DSPG may in part be due to a lower molar concentration
of plaque DSPG used in the assay. However, the magnitude of
the loss of plaque DSPG activity exceeds the expected effect of
the differences in molar concentration. The concern over the
potential influence of different chain lengths is further weak-
ened by (i) the correlation between structural components and
activity (discussed above) and (ii) the observation that 1 mg of
hexuronic acid/ml of normal artery biglycan (with two DS
chains per molecule) has approximately twice the activity of 1
mg of hexuronic acid/ml of decorin (which contains one DS chain
per molecule and was therefore assayed at effectively twice the
molar concentration of biglycan). Therefore, while chain size
may contribute to the observed differences in activity, struc-
tural features appear to play the main role.
Both the differences observed between biglycan and decorin
in the correlation of GAG composition and HCII stimulatory
activity and the potential influence of differences in DS chain
length prompted us to use a second method to assess the
interaction of HCII with DSPG. ACE measures the direct bind-
ing of GAG to protein in a GAG concentration-independent
manner. A single previous report measured a Kd of ;1.5 mM for
the HCII-DS interaction using kinetic methods (8). The current
findings confirm that the affinity of DS/DSPG for HCII is weak,
but for the samples analyzed by ACE there is a positive rela-
tionship between the activity measurements and interactions
with HCII in an ACE gel. Although the interaction is not strong
and may not represent a classical binding phenomenon, DS at
optimal concentrations stimulates a several thousand-fold rate
increase in a reaction that depends on an HCII-DS interaction
but not a thrombin-DS interaction (51, 52).
In recent publications, atherosclerotic plaques prone to
thrombosis have been identified as “vulnerable” atherosclerotic
lesions (53, 54) or type IV lesions (55). The presence of this
lesion type is associated with unstable angina, ischemic stroke,
myocardial infarction, and, potentially, sudden death (53, 54).
While therapeutic modulators to slow or delay the thrombotic
event are essential for eventually preventing extensive throm-
botic complications, the results of this study suggest that an
earlier intervention prior to the final stages of atherosclerosis
is possible. The understanding of why DS produced by smooth
muscle cells of developing atherosclerotic lesions does not
maintain the structural properties necessary for inhibition of
arterial wall thrombin by HCII may in turn permit the devel-
opment of therapies to reduce the rate of progression of ather-
osclerosis and thus reduce the number of vulnerable athero-
sclerotic lesions.
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